Table 2.
Effect of Tri-Sura-Phon tea drinking on body mass index, serum lipid profile, glucose and insulin levels, and liver function of healthy overweight volunteers.
| Parameters∗ | Tested group | Mean (SD) | ||
|---|---|---|---|---|
| Baseline | 4th week | 8th week | ||
| BMI (kg/m2) | Tri-Sura-Phon | 27.7 (4.5) | 27.6 (4.5) | 27.6 (4.5) |
| Placebo | 28.3 (4.0) | 28.0 (4.2) | 28.2 (4.1) | |
| Total cholesterol (mg/dL) | Tri-Sura-Phon | 223.7 (37.6) | 213.5 (29.2) | 201.3 (36.2)B |
| Placebo | 210.5 (33.0) | 213.6 (37.2) | 211.9 (42.6) | |
| Triglycerides (mg/dL) | Tri-Sura-Phon | 147.5 (74.3)3 | 79.3 (24.2)A,1,2 | 103.4 (40.2)B,1 |
| Placebo | 142.4 (75.9) | 125.6 (61.5) | 96.1 (37.5)B,C | |
| Low density lipoprotein (mg/dL) | Tri-Sura-Phon | 130.5 (40.5) | 129.7 (30.6) | 108.5 (37.6)B,C,3 |
| Placebo | 116.2 (35.5) | 125.0 (33.7) | 131.7 (44.0) | |
| High density lipoprotein (mg/dL) | Tri-Sura-Phon | 63.4 (12.8) | 68.0 (14.1)3 | 72.4 (13.4)B,1,3 |
| Placebo | 65.8 (10.0) | 67.6 (11.4) | 60.9 (13.6)C | |
| FBG (mg/dL) | Tri-Sura-Phon | 76.2 (6.1)1,2,3 | 84.1 (7.9)A,2,3 | 84.3 (8.4)B,2,3 |
| Placebo | 81.5 (12.0) | 91.4 (12.8)A | 91.2 (9.0)B | |
| Insulin level (uU/mL) | Tri-Sura-Phon | 8.9 (4.1) | 8.3 (3.5)3 | 9.9 (5.0) |
| Placebo | 10.9 (7.0) | 8.7 (4.2) | 10.9 (7.0) | |
| Albumin (gm/dL) | Tri-Sura-Phon | 4.6 (0.5)2 | 4.5 (0.5)2 | 4.1 (0.5)B,C,1,3 |
| Placebo | 4.5 (0.5) | 4.1 (0.4)A | 4.6 (0.5)C | |
| Total bilirubin (mg/dL) | Tri-Sura-Phon | 0.7 (0.4) | 0.9 (0.3)3 | 0.8 (0.4) |
| Placebo | 0.8 (0.5) | 0.9 (0.4) | 0.6 (0.5)C | |
| Direct bilirubin (mg/dL) | Tri-Sura-Phon | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) |
| Placebo | 0.0 (0.2) | 0.0 (0.0) | 0.0 (0.0) | |
| AST (U/L) | Tri-Sura-Phon | 20.1 (5.6)2,3 | 22.6 (6.8) | 19.8 (4.3)2,3 |
| Placebo | 22.7 (7.1) | 24.2 (5.1) | 24.3 (13.2) | |
| ALT (U/L) | Tri-Sura-Phon | 21.1 (14.0)3 | 20.8 (13.4)3 | 18.7 (13.5)3 |
| Placebo | 22.5 (11.6) | 20.7 (11.1) | 30.5 (26.5)C | |
| ALP (U/L) | Tri-Sura-Phon | 78.1 (20.1) | 76.0 (19.5) | 69.6 (21.3) |
| Placebo | 77.5 (15.7) | 74.8 (18.3) | 74.5 (17.0) | |
| GGT (U/L) | Tri-Sura-Phon | 25.0 (15.7) | 25.7 (16.0) | 25.1 (17.7) |
| Placebo | 25.5 (8.6) | 23.0 (8.3) | 26.0 (12.2) | |
Uppercase superscript letters indicate the significant differences in parameters between the baseline and week 4 (A) or the baseline and week 8 (B) or weeks 4 and 8 (C) within the treatment.
Superscript numbers indicate the significant differences between the parameters at baseline (1), week 4 (2), or week 8 (3) among the treatments.
∗BMI = body mass index, FBG = fasting blood glucose, AST = aspartate aminotransferase, ALT = alanine aminotransferase, ALP = alkaline phosphatase, and GGT = gamma-glutamyl transpeptidase.